BPC-157 and TB-500 are two of the most frequently compared research peptides — and two of the most frequently confused. Both surface in discussions of preclinical tissue-repair research, but they are fundamentally different molecules with different origins, different researched mechanisms, and — critically — very different evidence bases. This article compares what the published research actually describes for each.
Ver materiales de investigación: Tienda VONOX Labs
Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not for human consumption. This article is educational only and is not medical advice.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV, ~1419 Da) whose sequence is derived from a protective protein found in human gastric juice. First characterized by researchers at the University of Zagreb, it became notable for being stable in human gastric juice — unusual durability that led researchers to study it through multiple routes of administration in animal models.
BPC-157 research has investigated the peptide’s relationship with tendon and ligament healing, muscle repair, angiogenesis, nitric oxide signaling, gastrointestinal protection, and bone healing, including mechanisms involving angiogenesis/VEGF signaling, nitric oxide pathways, FAK-paxillin signaling in tendon fibroblasts, and growth hormone receptor expression in cultured tendon cells.
Unlike TB-500, the BPC-157 literature consists of studies that actually tested BPC-157 itself in animal and cell models. The caveat is the depth of that evidence: a 2025 systematic review screened over 500 papers and included 36 studies published between 1993 and 2024 — 35 were preclinical, and only one involved humans (a small, uncontrolled chart review with no control group). No randomized controlled human trial of BPC-157 has been completed.
What Is TB-500?
TB-500 is a synthetic 7-amino-acid peptide (sequence Ac-LKKTETQ, ~889 Da; CAS 885340-08-9) corresponding to the actin-binding domain (amino acids 17–23) of thymosin beta-4 — a naturally occurring 43-amino-acid protein found in essentially all cells and body fluids, described as the major G-actin-sequestering molecule in eukaryotic cells.
Here is the fact that defines the entire TB-500 evidence base: nearly all published research was conducted on full-length thymosin beta-4, not on the TB-500 fragment itself. A 2010 review identified the actin-binding domain as the region driving much of the migration, angiogenesis, and wound-healing activity — but a 2026 scoping review (McGuire et al.) noted that direct evidence on the fragment was limited, consisting largely of metabolite profiling and fibroblast screening. Conclusions drawn from the parent molecule do not automatically transfer to the fragment.
Thymosin beta-4 research has centered on cell migration, endothelial cell behavior, angiogenesis, dermal wound healing, corneal repair, cardiac tissue models, and inflammatory signaling. The most directly fragment-relevant finding: a 2003 study reported that the seven-amino-acid actin-binding motif displayed near-identical angiogenic activity to the full protein in cell migration and vessel-sprouting assays, while peptides lacking any portion of the motif were inactive.
BPC-157 vs. TB-500: Side-by-Side Comparison
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic 15-aa peptide; sequence derived from a protective protein in human gastric juice | Synthetic 7-aa fragment of thymosin beta-4’s actin-binding region (aa 17–23) |
| Peptide size | 15 amino acids, ~1419 Da | 7 amino acids (Ac-LKKTETQ), ~889 Da |
| Primary researched mechanism | Broad cytoprotection: angiogenesis/VEGF signaling, nitric oxide pathways, FAK-paxillin, growth hormone receptor expression | Actin regulation: G-actin sequestration, endothelial cell migration, ILK/Akt signaling |
| Main research areas | Tendon and ligament healing, muscle repair, gastrointestinal protection, bone healing | Dermal wound healing, corneal repair, cardiac tissue models, angiogenesis |
| Evidence level | Studies tested BPC-157 itself — but overwhelmingly in animals/cells; a 2025 systematic review found 35 of 36 studies preclinical | Most evidence is extrapolated from full-length thymosin beta-4 studies; fragment-specific literature is thin; no human trials of the fragment |
| Human data | One small uncontrolled chart review; no completed controlled efficacy trials | None for the fragment; full-length thymosin beta-4 reached Phase II trials in ocular and cardiac programs |
| Regulatory status | Not FDA approved anywhere | Not FDA approved anywhere; has not undergone human trials |
Key Differences: Mechanism, Evidence Base, and Research Focus
1. Different molecular identities
BPC-157 is a standalone 15-residue peptide with its own research identity. TB-500 is defined by what it is part of — seven residues from a 43-residue protein — and its research story is inseparable from the parent molecule’s literature.
2. Different researched mechanisms
BPC-157 has been investigated through several signaling pathways (angiogenesis, nitric oxide, FAK-paxillin) without a single established receptor mechanism. TB-500’s rationale starts from a precise, well-characterized function: thymosin beta-4’s regulation of the actin cytoskeleton — which is why the literature emphasizes cell migration and angiogenesis rather than broad cytoprotection.
3. The most important difference: what was actually tested
BPC-157’s studies tested BPC-157 itself. TB-500’s reputation rests on studies that tested thymosin beta-4, the full protein. The fragment’s direct literature is a small subset — metabolite profiling, fibroblast screening, and the 2003 angiogenesis-motif study. Treating parent-molecule findings as fragment findings is the single most common error in discussions of TB-500.
4. Overlapping but distinct research territories
Both compounds appear in musculoskeletal and wound-healing research. But their centers of gravity differ: BPC-157’s deepest literature is tendon, ligament, and gastrointestinal models; the thymosin beta-4 literature leans toward dermal wounds, corneal repair, and cardiac injury models — including the only human trials in either area, all of which tested the full protein.
What the Research Actually Shows for Each
BPC-157: consistent animal findings, no human trials
In a widely cited rat study, researchers transected the Achilles tendon and reported that BPC-157-treated animals showed improved biomechanical strength, better functional recovery, and superior collagen formation versus controls over 14 days. Related animal work reported improved ligament healing and protective effects in gastrointestinal damage models — a line of work a 2018 review summarized as BPC-157 acting as a “cytoprotective mediator.” But the 2025 systematic review sets the ceiling: 35 of 36 published studies were preclinical, and no controlled human efficacy trial has been completed.
TB-500 / thymosin beta-4: deep parent-molecule literature, thin fragment literature
The full-protein literature includes a 1997 study reporting thymosin beta-4 stimulated directional migration of endothelial cells; a 1999 rat wound study reporting 42% greater reepithelialization at day 4 and up to 61% greater at day 7 with increased angiogenesis; and a 2004 study reporting integrin-linked kinase activation with cardiac cell repair in animal myocardial-injury models. The human record belongs entirely to the full protein: a 2015 randomized, placebo-controlled Phase II trial of a thymosin beta-4 ophthalmic solution in dry eye, and an injectable thymosin beta-4 program (RGN-352) that advanced toward a Phase II trial in acute myocardial infarction. TB-500 as a standalone fragment has no published human trial data.
Why Researchers Study Them Together
BPC-157 and TB-500 are discussed together because their research territories overlap: both touch musculoskeletal repair, wound-healing models, and angiogenesis, and both are experimental probes of tissue-repair biology rather than candidates in clinical development.
The combination is also a topic of informal discussion. What the literature supports should be stated plainly: the two compounds have separate evidence bases that have never been merged in a published study. No peer-reviewed research has tested a BPC-157 + TB-500 combination in any model, and no synergy between them has been demonstrated.
Regulatory Status
Both compounds’ regulatory positions are worth stating plainly:
- Neither BPC-157 nor TB-500 is FDA approved for any indication, and no drug product based on either has been approved anywhere as a medicine.
- In 2023, both were designated as FDA 503A Category 2 bulk drug substances — a “may present significant safety risks” designation that prohibited their use in compounding by licensed U.S. pharmacies.
- In April 2026 the FDA removed both (among twelve peptides) from Category 2 — a procedural change tied to withdrawn nominations, not an authorization to compound.
- In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides — including both BPC-157 and TB-500 — for addition to the 503A Bulks List. That was an advisory recommendation only, not approval: the FDA must still complete notice-and-comment rulemaking, which has not begun. As of this writing, neither is on the 503A Bulks List.
- In sports, WADA prohibits thymosin beta-4 and its fragments, including TB-500, under category S2 at all times; USADA lists BPC-157 as prohibited for athletes due to the lack of human safety data.
Frequently Asked Questions
Are BPC-157 and TB-500 the same thing?
No. BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric-juice protein sequence. TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4’s actin-binding region. They are unrelated molecules with unrelated origins.
What is the main difference in how they’re researched?
BPC-157 has been studied as itself, mostly in animal models of tendon, ligament, muscle, and gastrointestinal healing. TB-500’s rationale comes from the thymosin beta-4 literature on actin regulation and cell migration — but nearly all of that research tested the full protein, not the fragment.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full 43-amino-acid protein; TB-500 is a synthetic fragment containing only its actin-binding domain (residues 17–23). Nearly all published research — including the wound-healing, ocular, and cardiac studies — was conducted on full-length thymosin beta-4, not the TB-500 fragment.
Are BPC-157 or TB-500 FDA approved?
No. Neither is FDA approved for any indication, and no drug product based on either has been approved anywhere. Both have been subject to FDA 503A compounding proceedings — all advisory, none constituting approval.
The Bottom Line
BPC-157 and TB-500 are two different research tools studying adjacent questions, not two versions of the same compound. BPC-157 is a gastric-juice-derived pentadecapeptide with a consistent — but entirely preclinical — animal literature centered on tendon, ligament, and gut models. TB-500 is a seven-residue fragment whose rationale is borrowed from the deep thymosin beta-4 literature on actin-mediated cell migration and wound healing — a literature that tested the parent protein, not the fragment.
The honest summary for both: promising preclinical signals, no human efficacy evidence, and no regulatory approval. Keeping those distinctions straight — what was tested, in what species, and in what form — is the difference between reading the research and reading its marketing.
For a deeper look at each compound’s individual literature, see our dedicated guides: BPC-157 and TB-500.
Explore BPC-157 & TB-500
Learn more about BPC-157 and TB-500 and explore our research-focused peptides at Vonox Labs: BPC-157 and TB-500
Research. Test. Learn.
Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.
Scientific References
- Starešinić M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/ (Rat Achilles transection; improved biomechanical strength, function, and collagen formation.)
- Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018;24(18):1990-2001. https://pubmed.ncbi.nlm.nih.gov/29879879/ (Review of BPC-157 as a proposed cytoprotective mediator in gut healing models.)
- Vasireddi H, Hahamyan A, Salata M, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21:485-495. https://pubmed.ncbi.nlm.nih.gov/40756949/ (36 studies, 1993–2024; 35 preclinical, 1 uncontrolled human chart review; no completed controlled human efficacy trials.)
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24:2144–2151. https://pubmed.ncbi.nlm.nih.gov/20179146/ (Review identifying the actin-binding domain — aa 17–23 — as the region promoting angiogenesis, wound healing, and cell migration.)
- Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17:2103-2105. https://pubmed.ncbi.nlm.nih.gov/14500546/ (The seven-amino-acid actin-binding motif showed near-identical angiogenic activity to full-length thymosin beta-4.)
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474–481. https://pubmed.ncbi.nlm.nih.gov/9194528/ (Thymosin beta-4 acted as a chemoattractant for endothelial cells.)
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta 4 accelerates wound healing. J Invest Dermatol. 1999;113:364–368. https://pubmed.ncbi.nlm.nih.gov/10469335/ (Rat full-thickness wound model; increased reepithelialization, collagen deposition, and angiogenesis.)
- Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466–472. https://pubmed.ncbi.nlm.nih.gov/15565145/ (ILK/Akt activation and cardiac cell repair in animal myocardial-injury models.)
- McGuire F, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Appl Sci. 2026;16(12):6202. https://doi.org/10.3390/app16126202 (Scoping review of 80 studies; 70 studied thymosin beta-4 vs. a single direct TB-500 study; direct fragment evidence limited to metabolite profiling and fibroblast screening.)
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. https://pubmed.ncbi.nlm.nih.gov/25826322/ (Randomized phase 2 trial of a thymosin beta-4 ophthalmic solution in severe dry eye — full-length protein, not the TB-500 fragment.)
Leave a Reply